BNP Paribas Financial Markets Has $53,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

BNP Paribas Financial Markets lessened its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 85.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,252 shares of the specialty pharmaceutical company’s stock after selling 37,044 shares during the period. BNP Paribas Financial Markets’ holdings in KalVista Pharmaceuticals were worth $53,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Aquatic Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC increased its position in KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 5,502 shares during the period. Legal & General Group Plc increased its position in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 1,494 shares during the period. Martin Worley Group acquired a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth $86,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 2,043 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Jones Trading reissued a “buy” rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $24.83.

KalVista Pharmaceuticals Trading Up 9.5%

Shares of NASDAQ:KALV opened at $12.92 on Tuesday. The company has a 50 day moving average of $11.91 and a 200 day moving average of $10.49. The stock has a market cap of $642.33 million, a P/E ratio of -3.55 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average price of $9.42 per share, with a total value of $235,500.00. Following the acquisition, the insider now owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. This trade represents a 0.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 6,669 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the sale, the chief executive officer now directly owns 287,811 shares of the company’s stock, valued at $3,445,097.67. The trade was a 2.26% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,399 shares of company stock valued at $182,054. Corporate insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).